The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy・Advisors have previously collaborated with MetrioPharm on strategic and scientific projects・Advisors bring expertise to further advance MetrioPharm ́s pipeline
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19・Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional benefits)・Results have been published in The Lancet Regional Health – Europe
FDA grants RPDD for the treatment of Duchenne muscular dystrophy (DMD)・MetrioPharm may be eligible for a priority review voucher with a market value in excess of USD 100 million
FDA grants orphan drug designation for MetrioPharm's lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)・DMD is a designated orphan disease in both Europe and the U.S.
Orally administered MP1032 with very favorable safety and tolerability profile・Compound equally effective as Remdesivir or Nirmatrelvir/Ritonavir as monotherapy
MetrioPharm is testing the efficacy of its lead compound MP1032 in DMD model・DMD is the most common and severe form of muscular dystrophy; it is a designated orphan disease in Europe and the USA
Corporate Slide Deck
Our corporate slide deck informs you about the MP1032 platform, our Pipeline and Development Strategy, as well as strong intellectual portfolio with 98 granted patents.
Investors
On our invest-platform you will find: The latest annual report, key figures and an overview of the company’s activities and strategy.